To evaluate the safety and efficacy of Graceptor ® in patients with kidney transplantation when converted from cyclosporine

Inclusion Criteria:

• Patients who are converted to Graceptor® from cyclosporine in the maintenance phase after kidney transplantation.

• Patients who meet one or more of following criteria

  1. Decrease in kidney function: GFR (or eGFR) less than 60 mL/min, or investigator's decision
  2. Hypertension: systolic/diastolic blood pressure 130/80 mmHg or more or treatment with an antihypertensive drug
  3. Hyperlipidaemia: LDL cholesterol 120 mg/dL or more, or treatment with an antihyperlipidemic drug
  4. Rejection: antibody mediated rejection by Banff classification borderline changes or more severe, or investigator's decision
  5. Other adverse events and patients who cannot continue cyclosporine treatment based on investigator's decision

Patients who are converted to Graceptor® from cyclosporine in the maintenance phase after kidney transplantation.

Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.